Bausch & Lomb Licenses rPlasmin from Talecris Biotherapeutics for Ophthalmic Use

30-Aug-2006

Bausch & Lomb and Talecris Biotherapeutics announced that Talecris has granted an exclusive worldwide license to Bausch & Lomb for recombinant Plasmin technology for use in ophthalmology. The companies will co-develop rPlasmin, a recombinant derivative of the human blood component Plasmin, which Bausch & Lomb believes may have potential for use in developing novel therapies for ocular conditions. Talecris is pursuing development of the technology in non-ocular applications, specifically to dissolve blood clots in veins and arteries.

The agreement expands the partnership announced in January 2005 in which Bausch & Lomb licensed plasma-derived Plasmin from Talecris' predecessor, Bayer Biological Products. Bausch & Lomb is enrolling patients in early-stage clinical trials to evaluate Plasmin's therapeutic potential to relieve retinal traction.

Under the terms of the agreement, Bausch & Lomb will be responsible for development of rPlasmin for use in ophthalmology. Bausch & Lomb will make milestone payments based on the development and registration progress, and pay ongoing royalties based on product sales. Further details of the agreement are confidential.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...